A Phase 1 interventional study of [^14C]-LY2940680 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-22.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single dose study of radiolabelled LY2940680 taken by mouth in healthy participants to study how the body absorbs and removes LY2940680 from the blood. This study is for research purposes only and is not intended to treat any medical condition.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 (\[\^14C\]-LY2940680)
Drug: [^14C]-LY2940680
Administered as solution by mouth
Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
The percentage of the total radioactive dose administered that was excreted in feces = \[(amount of radioactivity recovered in feces)/(radioactive dose administered)\]\*100.
Time frame: Predose up to 14 days postdose. Samples collected at 24-h intervals.
Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
The percentage of the total radioactive dose administered that was excreted in urine=\[(amount of radioactivity recovered in urine)/(radioactive dose administered)\]\*100.
Time frame: Predose up to 14 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.
Plasma PK of LY2940680 and LSN3185556: Maximum Observed Concentration (Cmax)
The Cmax of LY2940680 and its equipotent active metabolite in the free base form, LSN3185556, is reported.
Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter
PK of Radioactivity: Cmax
Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.
PK of LY2940680, LSN3185556, and Radioactivity: Time of Maximum Observed Concentration (Tmax)
The Tmax of LY2940680, LSN3185556, and total radioactivity in plasma are reported, as well as the Tmax for total radioactivity in whole blood.
Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.
Plasma PK of LY2940680 and LSN3185556: Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration [AUC(0 to Tlast)]
Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.
PK of Radioactivity: AUC(0 to Tlast)
AUC(0 to Tlast) of total radioactivity in plasma and whole blood are reported in nanograms\*hour equivalents per gram (ng\*h Eq/g).
Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.
Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Plasma
Relative abundance was expressed and calculated as the percentage of plasma sample radioactivity=\[(radioactivity in peak)/(radioactivity in sample)\]\*100. Metabolites with a relative abundance ≤6% are not reported.
Time frame: Day 1 up to 3 days postdose. Samples collected at 2, 3, 4, 6, and 8 h postdose on Day 1 and every 24 h thereafter.
Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Urine
Relative abundance was expressed and calculated as the percentage of administered dose excreted in urine=\[(percentage of radioactivity in peak)/100\]\*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.
Time frame: Predose up to 4 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.
Relative Abundance of LY2940680, the Metabolites of LY2940680, and LSN3185556 in Feces
Relative abundance was expressed and calculated as the percentage of the administered dose excreted in feces=\[(percentage of radioactivity in peak)/100\]\*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.
Time frame: Predose up to 8 days postdose. Samples collected at 24-h intervals.
| Milestone | [^14C]-LY2940680 |
|---|---|
| Started | 6 |
| Received study drug | 6 |
| Completed | 6 |
| Not completed | 0 |
The percentage of the total radioactive dose administered that was excreted in feces = \[(amount of radioactivity recovered in feces)/(radioactive dose administered)\]\*100.
| percentage of dose administered | [^14C]-LY2940680 |
|---|---|
| Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered | 82.7 ± 2.81 |
The percentage of the total radioactive dose administered that was excreted in urine=\[(amount of radioactivity recovered in urine)/(radioactive dose administered)\]\*100.
| percentage of dose administered | [^14C]-LY2940680 |
|---|---|
| Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered | 14.6 ± 1.68 |
The Cmax of LY2940680 and its equipotent active metabolite in the free base form, LSN3185556, is reported.
| nanograms per milliliter (ng/mL) | [^14C]-LY2940680 |
|---|---|
| Plasma LY2940680 | 831 ± 6 |
| Plasma LSN3185556 | 1210 ± 25 |
| nanogram equivalents per gram (ng Eq/g) | [^14C]-LY2940680 |
|---|---|
| Plasma Total Radioactivity | 2380 ± 7 |
| Whole Blood Total Radioactivity | 1520 ± 6 |
The Tmax of LY2940680, LSN3185556, and total radioactivity in plasma are reported, as well as the Tmax for total radioactivity in whole blood.
| h | [^14C]-LY2940680 |
|---|---|
| Plasma LY2940680 | 1.51 (1.00 to 3.00) |
| Plasma LSN3185556 | 2.50 (2.00 to 4.02) |
| Plasma Total Radioactivity | 2.00 (1.00 to 3.00) |
| Whole Blood Total Radioactivity | 2.00 (1.00 to 3.00) |
| nanograms*hour per milliliter (ng*h/mL) | [^14C]-LY2940680 |
|---|---|
| Plasma LY2940680 | 5680 ± 19 |
| Plasma LSN3185556 | 20400 ± 32 |
AUC(0 to Tlast) of total radioactivity in plasma and whole blood are reported in nanograms\*hour equivalents per gram (ng\*h Eq/g).
| ng*h Eq/g | [^14C]-LY2940680 |
|---|---|
| Plasma Total Radioactivity | 64800 ± 16 |
| Whole Blood Total Radioactivity | 38200 ± 18 |
Relative abundance was expressed and calculated as the percentage of plasma sample radioactivity=\[(radioactivity in peak)/(radioactivity in sample)\]\*100. Metabolites with a relative abundance ≤6% are not reported.
| percentage of sample radioactivity | [^14C]-LY2940680 |
|---|---|
| LY2940680 (parent) | 11.1 ± 2.54 |
| Metabolite M75 (LSN3185556) | 52.0 ± 5.14 |
| Metabolite M63 | 17.1 ± 1.71 |
Relative abundance was expressed and calculated as the percentage of administered dose excreted in urine=\[(percentage of radioactivity in peak)/100\]\*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.
| percentage of administered dose excreted | [^14C]-LY2940680 |
|---|---|
| LY2940680 (parent) | 0.105 ± 0.0937 |
| Metabolite M43 | 2.87 ± 0.816 |
| Metabolite M63 | 1.82 ± 0.740 |
Relative abundance was expressed and calculated as the percentage of the administered dose excreted in feces=\[(percentage of radioactivity in peak)/100\]\*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.
| percentage of administered dose excreted | [^14C]-LY2940680 |
|---|---|
| LY2940680 (parent) | 0.431 ± 0.313 |
| Metabolite M43 | 37.1 ± 1.65 |
| Metabolite M49 | 3.04 ± 0.861 |
| Metabolite M73 | 3.19 ± 1.43 |
| LSN3185556 | 2.90 ± 1.09 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| [^14C]-LY2940680 | — | 0/6 (0%) | 3/6 (50%) |
| Event | [^14C]-LY2940680 |
|---|---|
| DiarrhoeaGastrointestinal disorders | 2/6 |
| Abdominal distensionGastrointestinal disorders | 1/6 |
| Soft tissue massMusculoskeletal and connective tissue disorders | 1/6 |
| HeadacheNervous system disorders | 1/6 |
Enrolled participants who received study drug and had at least 1 safety assessment postdose.
| Age, Customized(Participants) | [^14C]-LY2940680 |
|---|---|
| 44 to 59 years | 6 |
| Sex: Female, Male(Participants) | [^14C]-LY2940680 |
|---|---|
| Female | 6 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | [^14C]-LY2940680 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | [^14C]-LY2940680 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | [^14C]-LY2940680 |
|---|---|
| United States | 6 |
The record gives a start of Jan 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2019, 6 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY2940680